Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15351137 | 0.86 | CNR1 (0.44) | CNR1SCN9ACNR2SCN5A | |
| SCHEMBL15351916 | 0.85 | DPP4 (0.50) | CNR1SCN9ACNR2SCN5A | |
| SCHEMBL28264256 | 0.84 | GABRA5 (0.47) | CNR1CNR2 | |
| SCHEMBL28012431 | 0.84 | CNR1 (0.44) | CNR1SCN9ACNR2SCN5A | |
| SCHEMBL15968271 | 0.84 | CNR1 (0.43) | CNR1SCN9ACNR2 | |
| SCHEMBL15350410 | 0.82 | CNR1 (0.40) | CNR1SCN9ACNR2SCN5A | |
| SCHEMBL5152841 | 0.82 | DPP4 (0.45) | — | |
| SCHEMBL2088604 | 0.80 | KDM4E (0.43) | CNR2 | |
| SCHEMBL1425265 | 0.79 | MAPK1 (0.46) | — | |
| SCHEMBL2716513 | 0.77 | SCN9A (0.46) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | CNR1 445/4885SCN9A 1166/4885CNR2 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.